Pathstone Holdings LLC Acquires 22,995 Shares of AstraZeneca PLC (NASDAQ:AZN)

Pathstone Holdings LLC increased its position in AstraZeneca PLC (NASDAQ:AZN) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 370,229 shares of the company’s stock after purchasing an additional 22,995 shares during the quarter. Pathstone Holdings LLC’s holdings in AstraZeneca were worth $24,259,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AZN. Banque Transatlantique SA acquired a new position in AstraZeneca during the fourth quarter worth $26,000. Albion Financial Group UT increased its position in AstraZeneca by 68.9% in the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after purchasing an additional 248 shares during the period. CoreCap Advisors LLC increased its position in AstraZeneca by 31.8% in the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after purchasing an additional 155 shares during the period. Crews Bank & Trust bought a new position in AstraZeneca during the fourth quarter worth about $55,000. Finally, Golden State Wealth Management LLC bought a new position in AstraZeneca during the fourth quarter worth about $55,000. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Down 2.2%

AZN stock opened at $66.23 on Thursday. The business’s 50 day simple moving average is $70.73 and its 200 day simple moving average is $69.57. The firm has a market capitalization of $205.40 billion, a PE ratio of 29.31, a PEG ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same period in the prior year, the firm posted $2.06 EPS. AstraZeneca’s quarterly revenue was up 7.2% on a year-over-year basis. As a group, research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on AZN. BNP Paribas began coverage on AstraZeneca in a report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 price objective on the stock. Morgan Stanley started coverage on AstraZeneca in a research report on Wednesday, February 12th. They issued an “overweight” rating on the stock. Finally, UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.